Q3 2017 Iovance Biotherapeutics Inc Earnings Call
Conference Call Iovance Biotherapeutics Inc
Iovance Biotherapeutics Inc Conference call or earnings call will be held on Oct 31, 2017 via an 800 number (toll-free). During the earnings conference call's session Iovance Biotherapeutics Inc will provide updated information and financial status.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Iovance Biotherapeutics Inc for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Our lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. A patient's immune system, particularly their TIL, plays an important role in identifying and killing cancer cells. TIL consist of a heterogeneous population of T cells that can recognize a wide variety of cancer-specific mutations and can overcome tumor escape mechanisms. TIL therapy involves growing a patient's TIL in special culture conditions outside the patient's body, or ex vivo, and then infusing the T cells back into the patient followed by infusion of six doses of interleukin-2 (IL-2).Read more Conference Call